Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scary.....
He’s not on a website. He’s just a CELZ investor who posted on ihub 3 times and I saved his posts because they were great reads. He happened to be an ED doctor finishing up in med school.
Another great description and explanation of stem cells and how it all works for CELZ.......you can't revisit this post enough....
Written by a CELZ investor/ ED Resident Doctor.
Stem Cells, Ethics, and the Future
Hey everyone!
So I just read through all the replies – wow! I’m glad for the positive feedback – if you have any medical questions related to stem cells, anatomy and physiology; or medicine in general I’d be more than willing to help. Just note that I'm limited to a few posts/week and won’t be able to get back to you for several days.
There’s a lot to read here, but you can also just skip ahead towards the end to know why this is relevant to CMTH’s ED, Amniostem, and StemSpine procedures.
Stem Cells:
Stem cells have been a growing interest in the field of medicine for quite some time now. Imagine, taking an essentially “blank” cell and programming it to repair the different systems in the body. This appears to be the Holy Grail of medicine, but why aren’t 100% of all our scientific efforts being placed in stem cell technology? The field of stem cell biology is actually rapidly blooming, but its initial stages of development was slowed because of the ethics involved in stem cell research (more specifically the source of these stem cells).
So what exactly makes a stem cell special?
1. They have the capacity to self-replicate.
2. They have the capacity to differentiate into progenitor cells which give rise to large numbers of mature, functionally replete cells necessary for carrying out specific tissue requirements (the process of amplification and differentiation)
3. Stem cells are also able to respond to external cues to meet the needs for more or less differentiated cells by exercising flexibility in the choice of the first two options, or to assume a state of quiescence or inactivity. (De Haan and Van Zant, 2002)
So these are essentially cells that can be reprogrammed to be more specialized cells in the body. The only problem is where we harvest stem cells.
Embryonic Stem Cells (ES):
Embryonic stem cells can generate into all the cell types in the body; thus, in theory, there are no restrictions on the organs that could be regenerated – this pretty much means limitless potential.
“…unused human blastocysts from fertility clinics could be used to derive new ES cell lines that are matched immunologically with potential transplant recipients. Alternatively, somatic cell nuclear transfer (“therapeutic cloning”) could be used to create ES cell lines that are genetically identical to those of the patient…” (Kasper, et al., 2015)
The problem is how these cells are harvested. As the name suggests, these are taken from embryos which raises fundamentally difficult questions about the definition of human life and if it’s ethical to use them. This is why, even though ES cells seem the most promising, they are not 100% validated by the scientific community due to the great diversity with respect to religious beliefs, concepts of individual rights, tolerance for uncertainty and risk, and boundaries for how scientific interventions should be used to alter the outcome of disease. Research into this type of stem cell is still going, but has slowed down significantly due to ethical constraints.
This brings us to our next type of stem cells.
Induced Pluripotent Stem Cells (iPS):
This are essentially mature, adult somatic cells that are converted (or “reprogrammed”) into pluripotent cells (cells capable of giving rise to different cell types). iPS cells share most of the same properties as ES cells, and they also bypass the ethical ramifications as well. So why aren’t these being used more? The problem is how they’re reprogrammed in the first place - viruses:
“Typically, viruses have been used to deliver these transcription factors, which presents a number of unique problems. The use of viral vectors to deliver reprogramming factors raises potential issues over the incorporation of viral DNA into the genome that could dampen iPS clinical applicability.” (Ebben et al., 2011)
Basically, the initial use of viruses to insert the transcription factors into somatic cells makes the resulting cells unsuitable for clinical use. The good news, however, is that a number of different strategies have been developed to circumvent this problem. In the end, the use of iPS cells in medicine is still being researched and still has some ways to go before it can be applied clinically.
Organ-Specific Multipotent Stem Cells (What CaverStem and StemSpine uses):
Multipotent stem cells are cells that have the capacity to self-renew by dividing and to develop into multiple specialized cell types present in a specific tissue or organ. The types of stem cells have the advantage of already being somewhat specialized so that the inducement of desired cell types may be easier. The disadvantage is that these cells are more limited in potentiality than ES or iPS cells and are difficult to obtain in large quantities from many organs.
The good news, however, is that bone marrow and blood are both relatively easy sources to harvest multipotent stem cells from. This is why substantial efforts have been devoted to developing techniques for using more easily obtainable stem cell populations, such as bone marrow mesenchymal stem cells (MSCs), CD34+ hematopoietic stem cells (HSCs), cardiac mesenchymal cells, and adipose-derived stem cells (ASCs), for use in regenerative strategies.
“Tissue culture evidence suggests that these stem cell populations may be able to generate differentiated cell types unrelated to their organ source (including myocytes, chondrocytes, tendon cells, osteoblasts, cardiomyocytes, adipocytes, hepatocytes, and neurons) in a process known as transdifferentiation.” (Kasper, et al., 2015)
CMTH, Inc., CaverStem and StemSpine:
Both CaverStem and StemSpine use bone marrow as their source of mesenchymal stem cells. StemSpine uses the same principles as CaverStem (both use mesenchymal stem cells) except that in StemSpine the stem cells are injected in to the spine to stimulate muscle and blood vessel regeneration. Here’s a summary of why this has tremendous value in terms of potential real-world application, and why research in this type of stem cell will continue to be strong:
1. Multipotent stem cells circumvents the ethical problems of embryonic stem cells, and is closer to clinical application compared to iPS cells
2. Mesenchymal stem cells are readily available in bone marrow.
3. Extraction of said stem cells can be done in the outpatient setting. Only local anesthesia is required.
4. No immunosuppressant drugs required (as for the case for organ transplants) as the stem cells are derived the patient.
CMTH, Inc. is pioneering a procedure in stem cell technology, a science that is still relatively young compared to the other fields in medicine.
I believe CaverStem alone will have a significant impact in ED and regenerative medicine, what more with StemSpine and Aminostem? What’s amazing is there are patents in place, meaning once stem cell therapy is more exposed, our position will be secured as other companies struggle to come up with their own research and methods in stem cell technology.
And think about this (this is all my own speculation, take it with a grain of salt): CaverStem and StemSpine (and maybe also Aminostem) will use the same kit to isolate the stem cells required for the procedure. As of now, CaverStem is targeted towards urologists (since they are concerned with ED). StemSpine will mostly target neurologists, and Aminostem will target internists and physicians of family medicine (both dealing with stroke). Since our scope will increase, the amount of doctors who may be interested will multiplied 2-3x (or more) depending on which field CMTH’s products are relevant to. Different practices will be ordering their own kits, or hospitals may order kits in bulk to use in their respective departments this technology applies to.
The potential here is outstanding. I still can’t believe this is under $1.
Happy 4th of July everyone!
This will be my last post for a while, I’ll see you all again when we’re at $0.10+!
____
Sources:
De Haan, G., & Van Zant, G. (2002). Stem cells from birth to death: The history and the future. Journal of the American Aging Association, 25(2), 79–86. http://doi.org/10.1007/s11357-002-0006-z [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3455756/pdf/11357_2002_Article_6.pdf]
Ebben, J. D., Zorniak, M., Clark, P. A., & Kuo, J. S. (2011). Introduction to Induced Pluripotent Stem Cells: Advancing the Potential for Personalized Medicine. World Neurosurgery, 76(3-4), 270–275. http://doi.org/10.1016/j.wneu.2010.12.055 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278994/#R10]
Kasper, D. L., Fauci, A. S., Hauser, S. L., Longo, D. L. 1., Jameson, J. L., & Loscalzo, J. (2015). Harrison's principles of internal medicine (19th edition.). New York: McGraw Hill Education.
Here's a great, in depth post from a CELZ long.....
Hi! An interested physician here!
I’ve been following this group and have been thinking of posting this for a while. This is my first post on this website actually, but of all the stocks I’ve followed I feel like $CELZ has the greatest potential to be $10.00 and above.
As my profile name suggests I am a physician (training as a 1st year resident) and I was introduced to this stock by one of our attendings who held a financial seminar earlier this year. As you can imagine, most of us graduate with crippling debt from medical school (where a good portion of our salary is shoveled to) which is why he held these seminars – to teach us some of his experience with bonds, stocks, and business, and the importance of investing our hard earned income.
So during his similar there were talks of some bio-medical stocks and Creative Medical Technology Holdings Inc (CELZ) was discussed as a potential stock to look at. There were others, but due to my field ED treatment seemed like familiar territory for me. I’ve since then looked into it and have read the various research and DD posted here and I’ve got to say I’m impressed! Today I want to contribute some knowledge from the inside perspective of the field everyone here is heavily invested in. Just note that this is WHY I BELIEVE this stock will grow, you can look at this any way you want but please do your own DD before you fully jump on board.
These are some of the things we learn in medical school up to residency and are found in most of our text books and step reviewers. My main source will be Harrison’s Principles of Internal Medicine, 19th edition since that’s what I currently use. I also took a look into the research articles on the CaverStem website themselves (most of them were just abstracts, but I managed to find the full articles and linked here to share in case you’re interested).
Overall, amazing work by the CaverStem team!
__
So first of all, how prevalent is ED?
In the National Health and Social Life Survey (NHSLS), which included a sample of men and women age 18–59, 10% of men reported being unable to maintain an erection (corresponding to the proportion of men in the MMAS reporting severe ED). Incidence was highest among men in the age group 50–59 (21%) and men who were poor (14%), divorced (14%), and less educated (13%). By 2025, experts predict that 322 million men will have ED worldwide. This is an increase from the estimated 152 million men with ED way back in 1995 (Aytac, McKinlay, & Krane RJ., 1999).
“The incidence of ED is also higher among men with certain medical disorders, such as diabetes mellitus, obesity, lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH), heart disease, hypertension” (Kasper, et al., 1999)
So we know that ED will continue to climb thanks to its close connection to the prevalent lifestyle diseases mentioned above (hypertension and diabetes being to most common). CMTH, Inc. (CELZ) is not only targeted here in the US, but will be spreading out internationally as well. Imagine how many patients this could potentially be used to relieve the burdens that come with ED.
So to know what is abnormal about erectile dysfunction (ED) we’ll need to know what the normal physiology is like. The normal male sexual function requires:
(1) An intact libido
(2) The ability to achieve and maintain penile erection
(3) Ejaculation
(4) Detumescence (tumescence means engorgement due to vascular congestion).
A lot of problems can come from (1) (no will to have sex in the first place), but those can usually be treated by treating the underlying cause; such as stopping certain conflicting medications or treating abnormal hormonal irregularities for example. Our focus of concern will be (2) as CaverStem targets the inability to get an erection and maintain it (the will is there, but the equipment is malfunctioning).
To understand what’s happening we should define what exactly leads to and maintains an erection.
The corpora cavernosa (or cavernous bodies) contain most of the blood in the penis during an erection. Penile erection depends on an increased flow of blood into the lacunar network within the cavernosa accompanied by complete relaxation of the arteries and corporal smooth muscle. The problem happens here when blood is unable to completely engorge these channels. This is essentially the target of CaverStem, hence the name (Cavernosa + Stem cells).
Of all of causes of ED the most common organic cause of ED is vascular disturbance. Atherosclerotic or traumatic arterial disease can decrease flow to the lacunar spaces, resulting in decreased rigidity and an increased time to full erection. Excessive outflow through the veins despite adequate inflow also may contribute to ED. Structural alterations to the fibroelastic components of the corpora may cause a loss of compliance and inability to compress the tunical veins. This condition may result from aging, increased cross-linking of collagen fibers induced by nonenzymatic glycosylation, hypoxemia, or altered synthesis of collagen associated with hypercholesterolemia.
So how does CaverStem fit in to all this?
“The possibility of using mesenchymal stem cells in the treatment of ED is enticing because these cells are known to secrete various growth factors that are beneficial in ED such as IGF-1 [133-135], VEGF [136], and FGF-2 [137], but also because of their anti-inflammatory activities [138], as well as possibility of differentiating into tissue relevant to the penile architecture [139].” (Ichim et al., 2013)
I really want to break this down for you:
IFG-1: Is commonly known to help build muscle and is also crucial in healing
FGF-2: This protein has been implicated in diverse biological processes, such as limb and nervous system development and wound healing.
And now here’s the really important one -
VEGF (Vascular endothelial growth factor): This stimulates the growth of blood vessels.
CaverStem HEALS and STIMULATES tissue and blood vessel growth, which has significant meaning the world of ED. Viagra and similar drugs work by increasing blood to the penis, and it works because just like a balloon you’re pumping it full of air. However, CaverStem essentially heals and repairs the damaged/blocked vessels by stimulating more to grow.
When introduced, Viagra and similar drugs were considered revolutionary in the world of ED. CaverStem, however, can one day be considered as a CURE.
This is why I consider this stock to be severely undervalued. If given the choice between a patch or a cure, which would you choose?
Also I know most of you have seen the procedure itself posted online. Bone marrow aspiration is a procedure that is commonly being done already for blood diseases, cancer, and other disorders. The only new thing that physicians need training for is how to operate the Magellan Cell Separator. Training shouldn’t be all that difficult.
I hope that this contributes something to your already established DD. Most of what I said could be taken from the articles posted on the official CaverStem website, but I wanted to simplify it because I know not a lot of people here work in the medical field.
I won’t be posting much here since between my rounds, patients, and other duties I only have free time to browse after my shift or during breaks. I will say, however, that I’m glad to be part of this ride with all the longs! Add me to the list of long holders: 300,000 strong. Not a lot compared to some of your millions, but it should be enough to help pay off part of my loan from medical school.
Sources:
I.A. Aytac¸ , J.B. Mckinlay And R.J. Krane (1999). The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU International. Retrieved from https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1464-410x.1999.00142.x
Ichim, T. E., Warbington, T., Cristea, O., Chin, J. L., & Patel, A. N. (2013). Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction? Journal of Translational Medicine, 11, 139. http://doi.org/10.1186/1479-5876-11-139
Kasper, D. L., Fauci, A. S., Hauser, S. L., Longo, D. L. 1., Jameson, J. L., & Loscalzo, J. (2015). Harrison's principles of internal medicine (19th edition.). New York: McGraw Hill Education.
Is this a shell?
Anyone know what caused the .57 to .01 drop from February to May?
And finally they mentioned money being used for advertising coming up! That’s what we’ve been missing! These Facebook posts aren’t cutting it. I can’t wait to see what type of commercials they roll out.
Easily...to the message I responded to.
I watched a ticker become OTC Pink current for the first time in years yesterday.
0 patents. $0 revenue and trading in the same channel range that we are trading.
CELZ is so ridiculously undervalued at this level. I have a feeling the way things are going, that success is just going to come in like a tsunami one day. It won’t be subtle. I’m waiting for THAT day.
Once we get StemSpine and AmnioStem rolled out and being used, we will have serious eyes on us. I do believe we will be bought out between 2022-2024 for $5-$10B. It’ll end up being $2.50-$5 per share payout. That’ll be great retirement money!
0 docs announced doesn’t mean 0 signed. And as we all know, CaverStem is about 10% of their patent portfolio. The rest is getting rolled out in waves.
I hear you! Hard for some to visualize that far out, especially with an OTC stock. I think everything will be golden by then as well. Accumulate these ridiculously priced shares and hold.
You aren’t missing anything, I just truly don’t think it’s going to be very much longer. They’ve said already that they’ve had them in hand for weeks now. First of all, if they weren’t good they wouldn’t release them. Therefore they wouldn’t mention that it’s in their plans to do.
Also, because they’ve had the results and had the research scientists looking over all of the accumulated data, my guess would be that it comes out no later than the end of next month. I’d like to say this month but it’s already half over, so I’ll say end of September.
But my opinion is that it will be soon. In comparison to 12 months, it’s soon.
Management plans to release clinical trials soon.
Hopefully they strategically were planning this. If they knew (which they obviously did) that their revenue wasn’t going to be great when released, hopefully they were just waiting to release clinical trials after the Q came out as a nice boost! Then maybe they can drop some nice AmnioStem strategic partner info for commercialization and roll north for a while. Hell, .017 is a 10 bagger from here and 6 months ago that was a regular daily pps. Funny thing is...nothing has changed since then except some dilution to afford commercialization of rock solid patents.
So I guess April-June weren't quite as big as we hoped. But this is still insanely undervalued and with an AmnioStem partner coming soon, we will finally be able to get the share price up once that happens. Hoping it comes soon. I'm sure they are anxious to be getting it out there as well. The fact that we will be partnering with somebody who can get name recognition out there is huge. Can't wait to see who it is.
Like was said last week.....Q3 is already half over, so hopefully they've been hard at work here lately. This is a big quarter and they know it.
Imo, the Guinness record will get 100X more exposure AFTER it has happened. That's what will spur downloads and interest. It's not really a matter of how many we have going into it. The more the better, but the record breaking event will garner TV news reports and inquiries of "what is all of this attention about with this new app".
It's more of an indirect free attention grab than it is to setting a humongous record.
Decline as in go lower than we opened? Of course it’s possible. But I do think in the very near future, we have news coming that will take us way out of where we sit now.
I sat and thought about the different offices plus Antonini’s office and tried figuring out a reasonable guess for this Q. I’m pretty optimistic about it, as well as some new info getting released with it or soon after.
In my experience, usually quiet either means sh*t is going bad or they are negotiating and very busy. The fact that Warbington is using his own money to get us to the next phase without taking on toxic loans, is a big deal. I think there’s bright sunshine on the horizon. Obviously they are and have been evaluating and negotiating with other companies to roll out AmnioStem, so I can’t think of anything more exciting than waiting to hear who it is we partner with. It could be the jolt this company needs to blast back up where it belongs. When it’s announced, the rise will be massive and fast. Why bother chasing? Secure your tickets now. Could come right when the Q is released.
I can’t wait!
Not to mention, like JBizzle posted on twitter, that $600M purchase by Bayer also proves that Pharma is watching stem cell companies and knows stem cells are the future. Don’t doubt that we have many big Pharma eyes already on us.
There’s no denying that stem cells are hot. We are the leader out of the gate in sexual dysfunction and our bag of patents has barely been opened yet.
You realize that BlueRock is a pre-clinical stem cell company that was just bought out by Bayer for $600M?
With CELZ pipeline of patents set to come out, our advanced clinical trials and already to market CaverStem and FemCelz procedures, I would say our valuation should be twice that at least.
That puts a potential buyout, if it were to happen soon, at around $1 per share. Obviously more as we roll out more procedures.
At $1 per share, how many millionaires do you think we have in here!!??
It costs you less than $2,000 right now to have 1 million shares. That could make you a millionaire in the not so distant future. Sounds like a deal to me. $$$$
Yep, been a rough ride down. But I think we finally are getting our floaties on and rising back to the top!
Volume is looking good. Even an expected $80-$100K revenue Q should pull this up another few tenths. Anything higher and I think we start cruising back up to the penny surface.
Yeah I have to be honest, this is the most solid it’s traded in a while. Looking strong for a move up with positive Q coming. Get in now or miss the ride back up.
I’m optimistic, but keep in mind that the 62 million shares traded on Friday were also at the lowest PPS in years. We tapped .0013 on Friday. I think a lot of that volume was people buying at .0013-.0014 and flipping at .0016-.0017 for 15-20% profits.
Well, considering that they have an approximate monthly burn rate of $100,000 and had to take a recent loan from Warbington, I’d say no. But the year isn’t over yet. Still over 4 months to go. This Q3 is almost half over already and until we get an update on how things are going recently, we will have no idea if we are still relying on the same handful of doctors to carry us higher or if they’ve been adding more as time goes by.
This is really the pivotal information we need to truly assess where we are right now.
Currently, we have been left by management to stand in a pitch black time warp room. When they finally open the blinds and we see some light, will there be positive change or no change=negative change?
That’s the gamble right now.
If you’re betting on positive change, then you’re holding and/or adding.
If you’re betting on no change/negative change, then you’ve either sold and are waiting for lower prices to come after the Q, you’re about to sell and wait for lower prices to buy back or you’re still holding and pissed.
That’s how I see it anyway.
That would be surprising, but it’s not out of the question.
This Q will really show, in my opinion, why there was deafening silence here. If it’s up near your estimate or higher, I think they had their nose to the grindstone and have been plugging away quietly. If it’s $95K-$125K, that’s going to be about what most expected. Nice increase. Par for the course. If it’s under $95K, I think this ugly last few months gets even uglier.
I agree. Was just responding to another post. Although it’s not out of the realm of possibility. Crazier things have happened to stocks with much less than a new cutting edge social media platform.
Until the MM’s stop being greedy and wearing this thing down whenever they choose, it won’t go far. They might let it breathe and get back to the .003’s, but be careful buying on the way up. They’ll just sink it again and again to the .001’s until we get positive trial results or the Q is exceptional. All my opinion. Great time to buy if you can, but I do believe the hold is going to be a long one. At this pace, a penny by Xmas would be a success. April 4, 2019 was the last time we were above a penny. Tough call to buy now. Lots of other tickers where you can grow your money now and come back here later to buy more imo.
If we average a 25% increase week to week, it would put us at $1.25 at Xmas.
There IS revenue. I’ve paid on the app so I’m 100% positive that there is revenue. No need for the next Q. TTCM is a revenue producing company.
Due next week on the 14th. Could file an extension, so it’s not a 100% given.
Nice post. On a side note....does anybody know what happens to patients that get treated and it doesn’t work for them at all? Are they just out the entire cost of the procedure? Sorry for your bad luck? Or is there some kind of insurance offered if it doesn’t work? That’s a pretty big $$ gamble for the average guy. Just wondering if this might be what’s holding back the amount of potential patients.
Nice!! So it’s still 4% Buy!!
The problem with going this low, is that every MM and flipper has loaded up down here. They’ll want small profits and we will have to churn for a while to get out of this range imo.
What the hell happened today. Was out all day long. Did someone get a preview of the Q? Or was this just a routine daily downward spiral? Volume looks super high, some more have dumped?
Just added. MM’s trying to shake shares before the show starts!!
I believe Don said over a month ago that they had results already and their research scientists were analyzing the data. This wasn’t said publicly, but in an email conversation. I have to agree that with the risk of delisting looming (at that time) that if the results were any good, that would’ve been the time to roll out the results. There were other parts of this conversation that didn’t sound very promising how he worded it. Basically that trial results didn’t really matter to them now since they were getting good results in the doctors offices.
So in my opinion, if you’re banking on trial results to boost this back up, you’re going to be disappointed. Unfortunately, like the bad guys in here have said, if trial results were worth posting, they’d have been out long ago. Not sure why they wouldn’t be. Could be anything from Pfizer paying someone to tamper or misinform about results to the fact that it just didn’t work on who they tested it on. If it averages working 70% of the time and they just happened to get a bunch of patients who are in the 30%, then that makes the results look way worse.
But bottom line, it’s going to take revenue to move this beast anywhere. Unfortunately, this one coming up isn’t going to move it and then there’s another 3 months until the next one and so on and so on.
Even if revenue grows amazingly by 100% every single quarter, we wouldn’t be self sufficient until a year from now (July 1).
This is just a much slower grow than most anticipated. We got caught in the hype train that
ran to .07 and the reality is that this is inching along with a lot of resistance from outside forces. It wouldn’t shock me if we didn’t
see .01 again until 2020.
I definitely think they can still be huge, but my time frame for that was way off! We might as well come back in a year and see where we are because these next 3-6 months will be slow and not much will be happening imo.
Yeah, I didn’t expect it to help. I’m sure we see .001’s by weeks end.